Biopharmaceutical firms struck 1,234 deals during the first half of 2013, up from 565 in the first half of the previous year. Licensing and joint ventures accounted for 30% of total transactions, according to a Recap report. The number of licensing and joint venture agreements increased 39% from the same period last year. Total deal value reached $73.3 billion, with $52.6 billion coming from mergers and acquisitions.
